Glucosephosphate Dehydrogenase Deficiency

Categories: Rare diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Glucosephosphate Dehydrogenase Deficiency

MalaCards integrated aliases for Glucosephosphate Dehydrogenase Deficiency:

Name: Glucosephosphate Dehydrogenase Deficiency 12 42 14
G6pd Deficiency 72 50 24 25 52 41
Glucose-6-Phosphate Dehydrogenase Deficiency 12 50 24 25
Deficiency of Glucose-6-Phosphate Dehydrogenase 25 69
Glucose 6 Phosphate Dehydrogenase Deficiency 25 29
Hemolytic Anemia Due to G6pd Deficiency 50
Deficiency of G-6pd 12
G6pdd 25


External Ids:

Disease Ontology 12 DOID:2862
MeSH 42 D005955
NCIt 47 C98933
UMLS 69 C2939465

Summaries for Glucosephosphate Dehydrogenase Deficiency

MedlinePlus : 41 glucose-6-phosphate dehydrogenase (g6pd) deficiency is a genetic disorder that is most common in males. about 1 in 10 african american males in the united states has it. g6pd deficiency mainly affects red blood cells, which carry oxygen from the lungs to tissues throughout the body. the most common medical problem it can cause is hemolytic anemia. that happens when red blood cells are destroyed faster than the body can replace them. if you have g6pd deficiency, you may not have symptoms. symptoms happen if your red blood cells are exposed to certain chemicals in food or medicine, certain bacterial or viral infections, or stress. they may include paleness jaundice dark urine fatigue shortness of breath enlarged spleen rapid heart rate a blood test can tell if you have it. treatments include medicines to treat infection, avoiding substances that cause the problem with red blood cells, and sometimes transfusions. nih: national library of medicine

MalaCards based summary : Glucosephosphate Dehydrogenase Deficiency, also known as g6pd deficiency, is related to hepatitis and sickle cell anemia. An important gene associated with Glucosephosphate Dehydrogenase Deficiency is G6PD (Glucose-6-Phosphate Dehydrogenase), and among its related pathways/superpathways are Metabolism and Glucose / Energy Metabolism. The drugs Primaquine and Artesunate have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and testes.

NIH Rare Diseases : 50 glucose 6 phosphate dehydrogenase (g6pd) deficiency is a hereditary condition in which red blood cells break down (hemolysis) when the body is exposed to certain foods, drugs, infections or stress. it occurs when a person is missing or has low levels of the enzyme glucose-6-phosphate dehydrogenase. this enzyme helps red blood cells work properly. symptoms during a hemolytic episode may include dark urine, fatigue, paleness, rapid heart rate, shortness of breath, and yellowing of the skin (jaundice). g6pd deficiency is inherited in an x-linked recessive manner and symptoms are more common in males (particularly african americans and those from certain parts of africa, asia, and the mediterranean). it is caused by mutations in the g6pd gene. treatment may involve medicines to treat infection, stopping drugs that are causing red blood cell destruction, and/or transfusions, in some cases. last updated: 5/8/2017

Genetics Home Reference : 25 Glucose-6-phosphate dehydrogenase deficiency is a genetic disorder that occurs almost exclusively in males. This condition mainly affects red blood cells, which carry oxygen from the lungs to tissues throughout the body. In affected individuals, a defect in an enzyme called glucose-6-phosphate dehydrogenase causes red blood cells to break down prematurely. This destruction of red blood cells is called hemolysis.

Disease Ontology : 12 A carbohydrate metabolic disorder that is characterised by abnormally low levels of glucose-6-phosphate dehydrogenase (abbreviated G6PD or G6PDH).

Wikipedia : 72 Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency), a form of which is known as favism... more...

Related Diseases for Glucosephosphate Dehydrogenase Deficiency

Diseases related to Glucosephosphate Dehydrogenase Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.5 G6PD HBB HP
2 sickle cell anemia 28.9 G6PD HBB HBG2 UGT1A1
3 hemolytic anemia due to g6pd deficiency 12.5
4 favism 11.1
5 49,xyyyy syndrome 10.4 G6PD PGD
6 toxic labyrinthitis 10.4 G6PD HP
7 raltegravir toxicity 10.3 SLCO1B1 UGT1A1
8 acute radiation syndrome 10.3 G6PD HBG2
9 microphthalmia, syndromic 13 10.3 G6PD HP
10 peripheral vascular disease 10.3 G6PD HBG2
11 renal artery disease 10.2 G6PD UGT1A1
12 hemorrhagic fever 10.2 HBB HP
13 nephrotic syndrome 14 10.2 G6PD HBB
14 glandular cystitis 10.1 G6PD SLCO1B1 UGT1A1
15 hepatitis b reinfection following liver transplantation 10.1 HBB HBG2
16 acute hydrops keratoconus 10.1 SLCO1B1 UGT1A1
17 unclassified vasculitis 10.0 HBB HBG2
18 tjp2-related familial hypercholanemia 10.0 HBB UGT1A1
19 hemolytic anemia 10.0
20 cyanosis, transient neonatal 10.0 HBB HBG2
21 adult malignant mesenchymoma 9.9 G6PD HBB HP
22 sialadenitis 9.9 G6PD H6PD
23 colorectal cancer 9.9
24 endometrial adenocarcinoma 9.9 HBB HP UGT1A1
25 hemoglobin h disease, nondeletional 9.9 G6PD HBB UGT1A1
26 geniculate ganglionitis 9.9 G6PD HBB HP
27 dermatomyositis 9.9 HBB UGT1A1
28 vagus nerve neoplasm 9.8 G6PD HBB UGT1A1
29 pyeloureteritis cystica 9.8 G6PD HP SLCO1B1 UGT1A1
30 pyelitis 9.8 G6PD HP SLCO1B1 UGT1A1
31 pyruvate kinase deficiency 9.7 G6PD HBG2
32 thalassemia-beta, dominant inclusion-body 9.7 HBB HBG2 UGT1A1
33 paraneoplastic polyneuropathy 9.6 G6PD H6PD
34 premature menopause 9.4 G6PD HBB HBG2 HP
35 tendinosis 9.4 G6PD HBB HBG2 HP
36 spastic paraplegia 8 9.4 G6PD HBB HBG2 UGT1A1
37 nodular degeneration of cornea 6.8 G6PD H6PD HBB HBG2 HP PGD

Graphical network of the top 20 diseases related to Glucosephosphate Dehydrogenase Deficiency:

Diseases related to Glucosephosphate Dehydrogenase Deficiency

Symptoms & Phenotypes for Glucosephosphate Dehydrogenase Deficiency

Drugs & Therapeutics for Glucosephosphate Dehydrogenase Deficiency

Drugs for Glucosephosphate Dehydrogenase Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Primaquine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-34-6 4908
Artesunate Approved Phase 4,Phase 3,Phase 1,Phase 2 88495-63-0 6917864 5464098
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
Dapsone Approved, Investigational Phase 4,Phase 3 80-08-0 2955
Artemether Approved Phase 4,Phase 2,Phase 3 71963-77-4 119380 68911
Lumefantrine Approved Phase 4,Phase 2,Phase 3 82186-77-4 6437380
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 58-14-0 4993
Sulfadoxine Approved Phase 4,Phase 3,Phase 1,Phase 2 2447-57-6 17134
Mefloquine Approved Phase 4,Phase 3,Phase 1,Phase 2 53230-10-7 4046
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 143 6006
15 Antioxidants Phase 4
Bilirubin Phase 4 635-65-4 5280352
17 Pharmaceutical Solutions Phase 4,Phase 2
18 Protective Agents Phase 4
19 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Antimalarials Phase 4,Phase 2,Phase 3,Phase 1
21 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Liver Extracts Phase 4
24 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
26 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1 50-63-5
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3
33 Folic Acid Antagonists Phase 4,Phase 3,Phase 1,Phase 2
34 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2
35 Artemisinine Phase 4,Phase 2,Phase 3,Phase 1
36 Artemisinins Phase 4,Phase 2,Phase 3,Phase 1
Dihydroartemisinin Phase 4,Phase 3,Phase 2,Phase 1 71939-50-9 6918483
Piperaquine Phase 4,Phase 3,Phase 2,Phase 1 4085-31-8 5079497
39 Antifungal Agents Phase 4,Phase 2,Phase 3
40 Artemether-lumefantrine combination Phase 4,Phase 2,Phase 3
41 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Cholagogues and Choleretics Phase 4
43 Gastrointestinal Agents Phase 4
44 N-Methylaspartate Phase 4
45 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
46 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
47 alanine Nutraceutical Phase 4
48 Aspartic Acid Nutraceutical Phase 4
Proguanil Approved Phase 3,Phase 1,Phase 2 500-92-5 4923
Amodiaquine Approved Phase 3,Phase 1,Phase 2 86-42-0 2165

Interventional clinical trials:

(show top 50) (show all 71)

id Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
3 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
4 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
5 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
6 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4 Dihydroartemisinin piperaquine (DHA PP);Primaquine
7 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
8 A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
9 Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Completed NCT02090036 Phase 4 Primaquine (For artemether-lumefantrine+primaquine arm);Placebo (For artemether-lumefantrine arm)
10 Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects Completed NCT02324738 Phase 4 Mefloquine and Dihydroartemisinin-piperaquine;Mefloquine
11 Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity Completed NCT02143934 Phase 4 Primaquine;Placebo;Chloroquine;Artemether Lumefantrine
12 Ethiopia Antimalarial in Vivo Efficacy Study 2012 Completed NCT01680406 Phase 4 Artemether-lumefantrine combination;Primaquine;Chloroquine
13 Malaria Elimination Pilot Study in Military Forces in Cambodia Recruiting NCT02653898 Phase 4 DHA-PIP;Primaquine;Artesunate + Mefloquine;Permethrin (Insecticide treated uniform)
14 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Not yet recruiting NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
15 The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders Terminated NCT02472509 Phase 4 Ursodeoxycholic Acid
16 A Trial on Supervised Primaquine Use in Ethiopia Withdrawn NCT02793388 Phase 4 Supervised primaquine treatment;Unsupervised primaquine treatment
17 Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation Unknown status NCT02498340 Phase 2, Phase 3
18 Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM) Completed NCT02174900 Phase 2, Phase 3 Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine;Artemether-Lumefantrine (AL) combination;Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
19 Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
20 Lapdap and Coartemether for Uncomplicated Malaria Completed NCT00118794 Phase 3 Chlorproguanil-dapsone (Lapdap);Lumefantrine-artemether (Coartemether )
21 Low Dose Primaquine for Clearance of Gametocytes Completed NCT01935882 Phase 2, Phase 3 Artemether-lumefantrine combination;Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine;Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
22 Eight Week Primaquine Regimen for the Treatment of Vivax Malaria Completed NCT00158587 Phase 3 primaquine
23 Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission Completed NCT02259426 Phase 3 Dihydroartemisinin-piperaquine combination (Artekin);Primaquine
24 Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
25 Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
26 P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
27 Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
28 Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria Recruiting NCT03056391 Phase 3 Paracetamol
29 Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria Not yet recruiting NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
30 Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia Terminated NCT02654730 Phase 2, Phase 3 Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient;Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient;Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient;Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal;Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal
31 Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali Completed NCT02535767 Phase 1, Phase 2 Primaquine
32 Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia Completed NCT00004381 Phase 2 tin mesoporphyrin
33 Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates With Hyperbilirubinemia Completed NCT01887327 Phase 2 stannsoporfin;Placebo
34 Phase2a Primaquine Dose Escalation Study Completed NCT01743820 Phase 2 dihydroartemisinin-piperaquine;0.125 mg/kg Primaquine;0.5 mg/kg Primaquine;0.25 mg/kg Primaquine;0.0625 mg/kg Primaquine
35 Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease Completed NCT01319448 Phase 1, Phase 2 Proguanil;mefloquine plus artesunate;Sulfadoxine-pyrimethamine plus amodiaquine
36 Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers Completed NCT00048477 Phase 2 L-NMMA and Sodium Nitrite
37 Rasburicase for Hyperuricemia Completed NCT00290992 Phase 2 rasburicase (SR29142)
38 Phase 2 Efficacy Study of Primaquine and Methylene Blue Completed NCT02831023 Phase 2 Sulphadoxine-pyrimethamine;0.25 mg/kg primaquine;Dihydroartemisinin-piperaquine;Methylene blue;Amodiaquine
39 DHEA in Synovial Sarcoma Patients Recruiting NCT02683148 Phase 1, Phase 2 DHEA
40 P.Vivax Treatment Trial Recruiting NCT02802813 Phase 1, Phase 2 Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ);Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo
41 Long-Term Safety Study of Tafenoquine Recruiting NCT03320174 Phase 2 Tafenoquine
42 A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria Recruiting NCT02563496 Phase 2 Tafenoquine;Chloroquine
43 Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency Completed NCT01668433 Phase 1 Regimens (Primaquine, Methylene blue)
44 G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine) Completed NCT01205178 Phase 1 Chloroquine;Primaquine;Tafenoquine
45 Pharmacokinetic Study of Primaquine in Healthy Obese Thai Adult Subjects Completed NCT02789566 Phase 1 Primaquine
46 Primaquine Pharmacokinetics in Lactating Women and Their Infants Completed NCT01780753 Phase 1 Primaquine
47 Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study) Unknown status NCT02361788
48 Comparing G6PD Tests Using Capillary Blood Versus Venous Blood Completed NCT02069236
49 Evaluation of Different G6PD Testing Platforms Completed NCT02104518
50 A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency Completed NCT00076323 Primaquine

Search NIH Clinical Center for Glucosephosphate Dehydrogenase Deficiency

Cochrane evidence based reviews: glucosephosphate dehydrogenase deficiency

Genetic Tests for Glucosephosphate Dehydrogenase Deficiency

Genetic tests related to Glucosephosphate Dehydrogenase Deficiency:

id Genetic test Affiliating Genes
1 Glucose 6 Phosphate Dehydrogenase Deficiency 29
2 Glucose-6-Phosphate Dehydrogenase Deficiency 24 G6PD

Anatomical Context for Glucosephosphate Dehydrogenase Deficiency

MalaCards organs/tissues related to Glucosephosphate Dehydrogenase Deficiency:

Lung, Heart, Testes, Skin, Spleen, Liver, Adipocyte

Publications for Glucosephosphate Dehydrogenase Deficiency

Variations for Glucosephosphate Dehydrogenase Deficiency

ClinVar genetic disease variations for Glucosephosphate Dehydrogenase Deficiency:

id Gene Variation Type Significance SNP ID Assembly Location
1 G6PD NM_000402.4(G6PD): c.653C> T (p.Ser218Phe) single nucleotide variant Pathogenic/Likely pathogenic rs5030868 GRCh37 Chromosome X, 153762634: 153762634
2 G6PD NM_000402.4(G6PD): c.576-60C> G single nucleotide variant Pathogenic rs2515904 GRCh37 Chromosome X, 153762771: 153762771
3 G6PD NM_000402.4(G6PD): c.1466G> T (p.Arg489Leu) single nucleotide variant Pathogenic rs72554665 GRCh37 Chromosome X, 153760484: 153760484
4 G6PD NM_000402.4(G6PD): c.961G> A (p.Val321Met) single nucleotide variant Pathogenic rs137852327 GRCh37 Chromosome X, 153761337: 153761337
5 G6PD NM_000402.4(G6PD): c.770G> T (p.Arg257Leu) single nucleotide variant Pathogenic rs137852328 GRCh37 Chromosome X, 153762340: 153762340
6 G6PD NM_000402.4(G6PD): c.1058T> C (p.Leu353Pro) single nucleotide variant Pathogenic rs76723693 GRCh37 Chromosome X, 153761240: 153761240

Expression for Glucosephosphate Dehydrogenase Deficiency

Search GEO for disease gene expression data for Glucosephosphate Dehydrogenase Deficiency.

Pathways for Glucosephosphate Dehydrogenase Deficiency

Pathways related to Glucosephosphate Dehydrogenase Deficiency according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
Show member pathways
2 11.92 G6PD HBB PGD UGT1A1
Show member pathways
11.82 G6PD H6PD PGD
4 11.59 G6PD PGD UGT1A1
Show member pathways
11.31 SLCO1B1 UGT1A1
Show member pathways
11.17 SLCO1B1 UGT1A1
Show member pathways
10.75 SLCO1B1 UGT1A1
Show member pathways
10.72 G6PD H6PD PGD PGM1
Show member pathways
9.91 G6PD PGD

GO Terms for Glucosephosphate Dehydrogenase Deficiency

Cellular components related to Glucosephosphate Dehydrogenase Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.5 HBB HBG2 HP
2 endocytic vesicle lumen GO:0071682 9.26 HBB HP
3 hemoglobin complex GO:0005833 9.16 HBB HBG2
4 tertiary granule lumen GO:1904724 9.13 HBB HP PGM1
5 haptoglobin-hemoglobin complex GO:0031838 8.62 HBB HP

Biological processes related to Glucosephosphate Dehydrogenase Deficiency according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.58 G6PD H6PD PGM1
2 cellular oxidant detoxification GO:0098869 9.49 HBB HP
3 response to hydrogen peroxide GO:0042542 9.48 HBB HP
4 positive regulation of cell death GO:0010942 9.46 HBB HP
5 acute-phase response GO:0006953 9.43 HP UGT1A1
6 glucose metabolic process GO:0006006 9.43 G6PD H6PD PGM1
7 oxygen transport GO:0015671 9.37 HBB HBG2
8 NADP metabolic process GO:0006739 9.32 G6PD H6PD
9 pentose-phosphate shunt, oxidative branch GO:0009051 9.16 G6PD PGD
10 pentose biosynthetic process GO:0019322 8.96 G6PD PGD
11 pentose-phosphate shunt GO:0006098 8.8 G6PD H6PD PGD

Molecular functions related to Glucosephosphate Dehydrogenase Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 9.32 HBB HBG2
2 NADP binding GO:0050661 9.26 G6PD H6PD
3 oxygen transporter activity GO:0005344 9.16 HBB HBG2
4 hemoglobin binding GO:0030492 8.96 HBB HP
5 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 G6PD H6PD

Sources for Glucosephosphate Dehydrogenase Deficiency

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....